Condensed Consolidated Statements of Operations - USD ($)		3 Months Ended		6 Months Ended
		Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Total revenues		$ 2,342	$ 206,929	$ 119,371	$ 464,107
Cost of revenues		(2,342)	(184,021)	(119,371)	(410,061)
Gross profit			22,908		54,046
Operating expenses:
Research and development		501,158	762,699	1,596,198	1,709,150
General and administrative		1,243,517	890,533	2,265,568	2,125,909
Total operating expenses		1,744,675	1,653,232	3,861,766	3,835,059
Loss from operations		(1,744,675)	(1,630,324)	(3,861,766)	(3,781,013)
Other income (expense):
Foreign currency transaction gain		473	3,722	1,682	3,356
Interest income (expense), net		35,925	(60,194)	64,767	(163,762)
Research and development incentives		(31,819)	6,209	(25,488)	12,657
Other income		43	2,354	43	43,223
Loss on extinguishment of debt			(393,791)		(393,791)
Change in fair value of convertible debt		95,551	460,000	260,933	460,000
Total other income (expense)		100,173	18,300	301,937	(38,317)
Net loss before income taxes		(1,644,502)	(1,612,024)	(3,559,829)	(3,819,330)
Income tax benefit					1,161,197
Net loss applicable to common stockholders		$ (1,644,502)	$ (1,612,024)	$ (3,559,829)	$ (2,658,133)
Basic net loss per share (in Dollars per share)	[1]	$ (1.31)	$ (3.56)	$ (3.71)	$ (8.35)
Diluted net loss per share (in Dollars per share)	[1]	$ (1.31)	$ (3.56)	$ (3.71)	$ (8.35)
Basic weighted average common shares outstanding (in Shares)	[1]	1,258,985	453,035	958,341	318,414
Diluted weighted average common shares outstanding (in Shares)	[1]	1,258,985	453,035	958,341	318,414
Grant revenue
Total revenues		$ 2,342	$ 206,929	$ 119,371	$ 464,107

[1] Adjusted to reflect the reverse stock split of one-for-sixteen effective June 5, 2024